Drug Discovery World
APRIL 25, 2024
It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.
Drug Discovery World
APRIL 18, 2024
It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
APRIL 4, 2024
It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.
Drug Discovery World
APRIL 10, 2024
It will take place on 2 May at 3pm BST, 10am EDT, 4pm CEST and will be presented by Ron Morena, Manager in Analytical Bioassay at Tanvex Biopharma CDMO, along with and Dr Neha Mishra, Senior Scientist in the BioProduction R&D team, Revvity. Characterizing binding properties of complex biomolecules is a critical step.
Pharmaceutical Technology
FEBRUARY 15, 2023
“At the small scale, manufacturing between 1 ml and 10 ml is typically not problematic , but it’s not straightforward to replicate processes and technologies once you want to produce tens of litres of formulations,” says Dr Crowe, who manages a team that develop novel analytical assays related to LNPs and nanomaterials for drug delivery.
Drug Discovery World
NOVEMBER 9, 2023
The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Ioanna Stamati, PhD, Team Leader, Bioconjugation, Antikor Biopharma, on: ‘Antibody fragment drug-conjugates (FDCs): Analysing novel formats with high DAR’.
Expert insights. Personalized for you.
52 
Let's personalize your content